-+ 0.00%
-+ 0.00%
-+ 0.00%

Sino Biopharm says China NMPA clears IM-101 hepatitis B drug for clinical trial

PUBT·07/23/2026 09:44:53
Listen to the news
Sino Biopharm says China NMPA clears IM-101 hepatitis B drug for clinical trial
  • Sino Biopharmaceutical won China NMPA clearance to start clinical trials of IM-101 injection, a PreS1 recombinant fusion protein for chronic hepatitis B.
  • The candidate is designed to restore HBV-specific immune responses, supporting the group’s push into functional-cure regimens for CHB.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260723-12254242), on July 23, 2026, and is solely responsible for the information contained therein.